By Stephen Adams, Optimum Strategic Communications Nature has been an inspiration behind the development of many drugs, starting with the humble aspirin, which was originally derived from willow bark. But what if we could learn the secrets of what gives some people the incredible ability to overcome the most serious diseases? What if we could […]
Highly experienced leader with demonstrated track record of antibody-based drug discovery and pipeline advancement Strengthens Commit’s leadership team after emerging from stealth with €16m seed financing Dr Pedersen will spearhead research and development of Commit’s BiCETM technology as the Company moves towards drug candidate (DC) nomination Aarhus, Denmark, 15 October 2024 – Commit Biologics (“Commit”), […]
Commit Biologics is pioneering a novel approach to activating the complement component of the immune system to treat cancer and autoimmune diseases Poster to be presented on Commit’s Bispecific Complement Engaging (BiCE™) platform Aarhus, Denmark, 10 June 2024 – Commit Biologics (“Commit”), a pioneer in the activation of the complement system to treat cancer […]
Cambridge, UK, 06 June 2024 – Alchemab Therapeutics (Alchemab), an antibody discovery company identifying naturally occurring antibodies from individuals resilient to disease, today announces that it has been awarded a grant of US$595,000 by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to support its Parkinson’s disease program. The grant will fund research performed at […]
Cambridge, UK, 14 May 2024 – Alchemab Therapeutics (Alchemab), an antibody discovery company identifying naturally occurring antibodies from individuals resilient to disease, today announces the publication of a peer reviewed article titled “Predictability of B cell clonal persistence and immunosurveillance in breast cancer” in the journal Nature Immunology. The senior author Rachael Bashford-Rogers is a co-founder of […]
